Navigation Links
Current Severe Outbreaks of Foot and Mouth Disease Predicted by Replikins' BioRadar(TM) One Year in Advance (June 2009)

LONDON, July 16 /PRNewswire/ -- BioRadar UK Ltd. predicted one year ago the current severe Foot and Mouth Disease (FMD) outbreaks after recording an increase of the Replikin Count (ref. 1) of the FMD Virus (FMDV) to its highest level in 52 years. Based on these findings, a new synthetic Replikins Trans-Strain FMD Vaccine, called TransFMDV(TM), has been developed and is now available. The announcement was made at the recent Biorbis Conference on Vaccine Production and Manufacturing in Amsterdam, the Netherlands. The conference was attended by major pharmaceutical company executives to examine how vaccine production could be accelerated in view of the problem last year of responding "too little, too late" to the H1N1 influenza pandemic.

The Foot and Mouth Disease outbreaks now rampant in Asia are moving west to the Middle East and south to Africa. The last major FMD outbreak followed the same path of spread, and cost approximately 17 billion pounds sterling when it reached the U.K. in 2001.

BioRadar(TM) also gave warning one year in advance (January 2009, ref. 2) of the re-emergence of H5N1 (bird) influenza. H5N1 is now producing outbreaks in chickens in 63 countries. In Egypt, H5N1 has appeared in 31 human cases (40% mortality). The accuracy of these predictions is supported by the fact that BioRadar(TM) predicted, one year in advance, the H1N1 pandemic of 2009.

Dr. Samuel Bogoch, chairman of BioRadar UK Ltd., reported to the Amsterdam conference that the new technology gives accurate advance notice of virus outbreaks.

Further, two Replikins synthetic vaccines have been found by others to be effective against H5N1 influenza in chickens (TransFlu(TM)) (ref. 3) and against lethal Taura Syndrome virus in shrimp. These synthetic non-biological methods produce Replikins vaccines in 7 days rather than the six to eight months required by older biological methods. Regardless of which method of vaccine production is used, even using standard biological methods, one year of additional time to produce and test vaccines is now possible.

United Kingdom's UK Trade and Investment (UKTI) announced that BioRadar UK Ltd. has "one of the first reliable systems for accurately predicting the strain of future flu outbreaks together with the severity and duration." Subscriptions to the Replikins BioRadar Global Surveillance System(TM) are being received by BioRadar UK Ltd.

Contact: John McKenney,, 617-536-0220


1. Bogoch S. and Bogoch ES. Replikins: the chemistry of rapid replication. Begell House, N.Y. 2005. Library of Congress.  

2. Website:, Replikins Press - 35 online reports, 2006-2010.

3. Jackwood, M. et al. Efficacy of a Replikin Peptide Vaccine Against Low Pathogenicity Avian Influenza H5 Virus. doi: 2009.10.637/8892-042509; full paper in Avian Diseases 2009.

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at

SOURCE Replikins
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. FDA Approves First-of-Its-Kind HIV Test Which Can Detect HIV Days Earlier Than Current U.S. Tests
2. Oncolytics Biotech(R) Inc. Completes Patient Enrollment in Phase I Portion of U.S. Phase I/II Recurrent Malignant Gliomas Clinical Trial
3. The hot -- and cold -- interventional radiology treatments for recurrent prostate cancer
4. Penn material scientists turn light into electrical current using a golden nanoscale system
5. Waukesha Electric partners with SuperPower and UH to build fault current limiting superconducting transformer for Dept. of Energy
6. New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents
7. Beike Biotech Adds International Executives to Strengthen Current Technologies and Develop Future Pipeline
8. Enobia Raises US$50M from Current Investors in Series C Financing
9. Onyx Pharmaceuticals Announces Pricing of Concurrent Offerings of Four Million Shares of Common Stock and $200 Million Principal Amount of Convertible Senior Notes
10. ULURU Discussions to Acquire York Pharma, plc Are Currently Terminated
11. 2009 Pharma ChemOutsourcing Show Attendance Up an Astounding 60% Despite Current Recession
Post Your Comments:
(Date:11/25/2015)... HOLLISTON, Mass. , Nov. 25, 2015 ... HART ), a biotechnology company developing bioengineered organ implants ... McGorry will present at the LD Micro "Main ... 2:30 p.m. PT. The presentation will be webcast live ... Management will also be available at the conference for ...
(Date:11/25/2015)... November 25, 2015 The ... is a professional and in-depth study on the ...      (Logo: ) , ... industry including definitions, classifications, applications and industry chain ... the international markets including development trends, competitive landscape ...
(Date:11/24/2015)... -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting ... on Wednesday, December 2 at 9:30 a.m. ET/6:30 a.m. ... will provide a corporate overview. th Annual Oppenheimer ... p.m. ET/10:00 a.m. PT . Jim Mazzola , vice ... overview. --> th Annual Oppenheimer Healthcare Conference in ...
(Date:11/24/2015)... Global, Inc., a worldwide provider of clinical research services headquartered in ... company has set a new quarterly earnings record in Q3 of ... for Q3 of 2014 to Q3 of 2015.   ... with the establishment of an Asia-Pacific office ... Kingdom and Mexico , with the ...
Breaking Biology Technology:
(Date:11/16/2015)... , Nov 16, 2015  Synaptics Inc. ... human interface solutions, today announced expansion of its ... ™ touch controller and display driver integration ... of smartphones. These new TDDI products add to ... (HD resolution), TD4302 (WQHD resolution), and TD4322 (FHD ...
(Date:11/12/2015)... , Nov. 11, 2015   Growing need ... analytical tools has been paving the way for ... determination of discrete analytes in clinical, agricultural, environmental, ... being predominantly used in medical applications, however, their ... sectors due to continuous emphasis on improving product ...
(Date:11/10/2015)... About signature verification Signature ... identify and verify the identity of an individual ... secure and accurate method of authentication and is ... because each individual,s signature is highly unique. Signature ... signature of an individual is compared and matched ...
Breaking Biology News(10 mins):